FDA approves new Alzheimer's PET imaging agent from Lantheus

The U.S. FDA has approved a new PET imaging agent from Lantheus specifically for Alzheimer's disease, enabling improved diagnosis and patient management.

This Wire brief sits within Fusion42's coverage of Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.